Goldman Names Health Stocks With Promising Covid-19 Efforts
(Bloomberg) -- Goldman Sachs analysts have created a basket of more than 20 health-care companies developing treatments, vaccines and tests for the coronavirus pandemic.
The list “is not all-encompassing,” but the analysts say it “provides a wide-enough, representative, and global sample of names with newsflow likely over the next 12 months.” Goldman expects the basket will continue to command a “goodwill” premium while hedging against individual stock volatility.
At the top of Goldman's list is Gilead Sciences Inc. and Regeneron Pharmaceuticals Inc., which are expected to report clinical results from experimental Covid-19 treatments this month. Moderna Inc. and Johnson & Johnson have the most promising vaccines, analysts said.
The other companies are Abbott Laboratories, Adaptive Biotechnologies Corp., Alnylam Pharmaceuticals Inc., Becton Dickinson and Co., BioNTech SE, CSL Ltd., Danaher Corp., Fujifilm Holdings Corp., Grifols SA, Incyte Corp., Kiniksa Pharmaceuticals Ltd., Laboratory Corp. of America, Novartis AG, Pfizer Inc., Quest Diagnostics Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Co., Thermo Fisher Scientific Inc., Vir Biotechnology Inc. and Wuxi Biologics Cayman Inc.
The U.S. Food and Drug Administration is expediting development and review of new products to fight Covid-19, while President Donald Trump has extolled the benefits of unapproved drugs at press conferences. “Several names on this list could continue to see sentiment tailwinds from a combination of potentially supportive government commentary and/or easing regulatory hurdles,” analysts led by Asad Haider wrote in a note.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.